Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Ended earlyNCT00202995
What this trial is testing

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 91
Not applicableStudy completedNCT04756687
What this trial is testing

Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Biogen 1,507
Not applicableStudy completedNCT04580381
What this trial is testing

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University Hospital, Caen 500
Large-scale testing (Phase 3)Looking for participantsNCT05834855
What this trial is testing

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDemyelinating Autoimmune Diseases, CNS+3 more
Amsterdam UMC, location VUmc 200
Large-scale testing (Phase 3)Study completedNCT01307332
What this trial is testing

Advanced MRI Measures of Repair in Alemtuzumab Treated Patients

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of British Columbia 27
Not applicableLooking for participantsNCT06919900
What this trial is testing

Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (Relapsing Remitting)
Georgia State University 64
Testing effectiveness (Phase 2)UnknownNCT00217295
What this trial is testing

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Multiple Sclerosis Institute 30
Testing effectiveness (Phase 2)UnknownNCT02587806
What this trial is testing

Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Novo Cellular Medicine Institute LLP 69
Not applicableStudy completedNCT05351411
What this trial is testing

Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Firat University 60
Early research (Phase 1)Study completedNCT01244139
What this trial is testing

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Biogen 47
Not applicableNot Yet RecruitingNCT07734675
What this trial is testing

Sociocognitive Intervention and Rehabilitation Program in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Sonia Batista 130
Post-approval studies (Phase 4)Study completedNCT01578330
What this trial is testing

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Who this might be right for
Multiple SclerosisRelapsing-Remitting
Novartis Pharmaceuticals 42
Not applicableStudy completedNCT05658601
What this trial is testing

Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bristol-Myers Squibb 104
Testing effectiveness (Phase 2)Study completedNCT00097760
What this trial is testing

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 110
Post-approval studies (Phase 4)Study completedNCT01201343
What this trial is testing

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis, Relapsing, Remitting
Merck KGaA, Darmstadt, Germany 79
Not applicableActive Not RecruitingNCT05925049
What this trial is testing

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis
Biogen 400
Not applicableLooking for participantsNCT03401879
What this trial is testing

Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingOptic Neuritis
Medical University of Vienna 50
Large-scale testing (Phase 3)Study completedNCT03093324
What this trial is testing

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 506
Early research (Phase 1)UnknownNCT02364986
What this trial is testing

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
PD Dr. Marcus Müller 50
Early research (Phase 1)Study completedNCT01431937
What this trial is testing

Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GlaxoSmithKline 40
Next Page